The DOCK2 Knockout PaTu 8988t Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population targeting DOCK2 in the human pancreatic adenocarcinoma line PaTu 8988t. This polyclonal knockout cell population offers a ready-to-use loss-of-function model for dissecting DOCK2-dependent signaling in a metastatic cancer context without requiring monoclonal isolation. The CRISPR/Cas9-mediated gene disruption generates a heterogeneous pool that approximates therapeutic DOCK2 inhibition.
The PaTu 8988t cell line, established from a liver metastasis of a pancreatic adenocarcinoma, provides a model of advanced pancreatic cancer with characteristic oncogenic KRAS G12V and TP53 mutations. These epithelial cells are widely employed to investigate tumor cell invasion, dissemination, and molecular mechanisms driving metastasis, and are a standard system for pancreatic cancer drug discovery.
DOCK2 is a Rac-specific guanine nucleotide exchange factor that controls actin cytoskeleton dynamics and cell migration. It operates downstream of chemokine receptors (e.g., CXCR4, CCR7) and interacts with ELMO1 and CRK to activate Rac1/2. Activated Rac stimulates PAK kinases and the WAVE?CArp2/3 complex, leading to actin polymerization and lamellipodia formation. The DOCK2?CELMO1?CRAC1 axis also regulates LIMK/cofilin-mediated actin remodeling and is essential for immune cell chemotaxis and tumor cell invasion. Consequently, DOCK2 functionally links extracellular chemotactic signals to directional cell movement and matrix degradation.
In the PaTu 8988t pancreatic cancer model, DOCK2??s function in Rac-driven actin remodeling likely contributes to the invasive and metastatic phenotype, particularly under the influence of the mutant KRAS and TP53 background. Disruption of DOCK2 in this metastatic cell line offers a unique opportunity to study DOCK2-dependent migration, integrin-mediated adhesion, and potential roles in immune evasion or chemokine-directed motility within the tumor microenvironment. Moreover, given the central role of KRAS in pancreatic cancer, DOCK2 may integrate oncogenic signaling with cytoskeletal rearrangements, further promoting metastatic dissemination.
Researchers can assess DOCK2 activity by measuring Rac-GTP levels and phospho-PAK via Western blot, evaluate cell migration and invasion using Transwell assays, and visualize F-actin organization through immunofluorescence. Co-immunoprecipitation with ELMO1 or RAC1, phospho-signaling arrays, chemotaxis assays, and RNA-seq for metalloproteinases and immune-related transcripts further expand experimental possibilities. Additionally, these polyclonal knockout cells can be applied in co-culture models or in vivo xenograft studies to examine DOCK2??s role in tumor progression. They are well-suited for inhibitor screens and detailed mechanistic studies of pancreatic cancer metastasis. For additional information, contact Ascent Research.
